Citadel Advisors’s Integra LifeSciences IART Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.49M | Buy |
476,701
+220,894
| +86% | +$2.43M | ﹤0.01% | 4520 |
|
|
2025
Q4 | $3.18M | Buy |
+255,807
| New | +$3.4M | ﹤0.01% | 5064 |
|
|
2025
Q3 | – | Sell |
-270,062
| Closed | -$3.7M | – | 13362 |
|
|
2025
Q2 | $3.31M | Buy |
270,062
+52,496
| +24% | +$762K | ﹤0.01% | 4813 |
|
|
2025
Q1 | $4.78M | Buy |
217,566
+131,848
| +154% | +$3.1M | ﹤0.01% | 3952 |
|
|
2024
Q4 | $1.94M | Buy |
85,718
+53,306
| +164% | +$1.16M | ﹤0.01% | 5692 |
|
|
2024
Q3 | $589K | Sell |
32,412
-218,071
| -87% | -$5.05M | ﹤0.01% | 7919 |
|
|
2024
Q2 | $7.3M | Buy |
250,483
+167,252
| +201% | +$4.96M | ﹤0.01% | 3214 |
|
|
2024
Q1 | $2.95M | Buy |
83,231
+5,633
| +7% | +$225K | ﹤0.01% | 4820 |
|
|
2023
Q4 | $3.38M | Buy |
+77,598
| New | +$3.05M | ﹤0.01% | 4451 |
|
|
2023
Q3 | – | Sell |
-398,861
| Closed | -$16.4M | – | 14638 |
|
|
2023
Q2 | $16.4M | Buy |
398,861
+284,706
| +249% | +$13.7M | ﹤0.01% | 2089 |
|
|
2023
Q1 | $6.55M | Sell |
114,155
-60,006
| -34% | -$3.38M | ﹤0.01% | 3376 |
|
|
2022
Q4 | $9.77M | Sell |
174,161
-102,948
| -37% | -$5.24M | ﹤0.01% | 2878 |
|
|
2022
Q3 | $11.7M | Buy |
277,109
+18,005
| +7% | +$922K | ﹤0.01% | 2539 |
|
|
2022
Q2 | $14M | Buy |
259,104
+59,329
| +30% | +$3.56M | ﹤0.01% | 2260 |
|
|
2022
Q1 | $12.8M | Buy |
199,775
+154,676
| +343% | +$10.2M | ﹤0.01% | 2576 |
|
|
2021
Q4 | $3.02M | Buy |
45,099
+36,890
| +449% | +$2.5M | ﹤0.01% | 5319 |
|
|
2021
Q3 | $562K | Buy |
+8,209
| New | +$580K | ﹤0.01% | 9585 |
|
|
2021
Q2 | – | Sell |
-4,948
| Closed | -$350K | – | 13995 |
|
|
2021
Q1 | $342K | Sell |
4,948
-45,674
| -90% | -$3.09M | ﹤0.01% | 10534 |
|
|
2020
Q4 | $3.29M | Buy |
50,622
+13,331
| +36% | +$717K | ﹤0.01% | 4432 |
|
|
2020
Q3 | $1.76M | Sell |
37,291
-168,215
| -82% | -$8M | ﹤0.01% | 4961 |
|
|
2020
Q2 | $9.66M | Sell |
205,506
-27,651
| -12% | -$1.36M | ﹤0.01% | 2261 |
|
|
2020
Q1 | $10.4M | Buy |
233,157
+130,183
| +126% | +$6.83M | ﹤0.01% | 1807 |
|
|
2019
Q4 | $6M | Sell |
102,974
-70,831
| -41% | -$4.22M | ﹤0.01% | 2858 |
|
|
2019
Q3 | $10.4M | Sell |
173,805
-27,631
| -14% | -$1.65M | ﹤0.01% | 2168 |
|
|
2019
Q2 | $11.3M | Buy |
201,436
+79,351
| +65% | +$4.09M | 0.01% | 2049 |
|
|
2019
Q1 | $6.8M | Sell |
122,085
-149,913
| -55% | -$7.64M | ﹤0.01% | 2560 |
|
|
2018
Q4 | $12.3M | Buy |
271,998
+196,492
| +260% | +$10.8M | 0.01% | 1679 |
|
|
2018
Q3 | $4.97M | Buy |
75,506
+69,719
| +1,205% | +$4.33M | ﹤0.01% | 3015 |
|
|
2018
Q2 | $373K | Buy |
+5,787
| New | +$358K | ﹤0.01% | 6855 |
|
|
2017
Q2 | – | Sell |
-539,185
| Closed | -$22.7M | – | 7719 |
|
|
2017
Q1 | $22.7M | Buy |
539,185
+519,561
| +2,648% | +$22.2M | 0.02% | 861 |
|
|
2016
Q4 | $842K | Buy |
+19,624
| New | +$798K | ﹤0.01% | 4096 |
|
|
2016
Q2 | – | Sell |
-472,078
| Closed | -$15.9M | – | 7045 |
|
|
2016
Q1 | $15.9M | Buy |
472,078
+112,238
| +31% | +$3.5M | 0.02% | 883 |
|
|
2015
Q4 | $12.2M | Buy |
359,840
+72,112
| +25% | +$2.25M | 0.01% | 1133 |
|
|
2015
Q3 | $8.57M | Buy |
+287,728
| New | +$9M | 0.01% | 1465 |
|
|
2015
Q2 | – | Sell |
-1,960
| Closed | -$52.2K | – | 8866 |
|
|
2015
Q1 | $49K | Sell |
1,960
-45,988
| -96% | -$1.09M | ﹤0.01% | 7390 |
|
|
2014
Q4 | $1.06M | Sell |
47,948
-18,200
| -28% | -$369K | ﹤0.01% | 3694 |
|
|
2014
Q3 | $1.34M | Sell |
66,148
-4,902
| -7% | -$97.6K | ﹤0.01% | 3336 |
|
|
2014
Q2 | $1.37M | Buy |
71,050
+19,718
| +38% | +$367K | ﹤0.01% | 3124 |
|
|
2014
Q1 | $965K | Sell |
51,332
-135,280
| -72% | -$2.61M | ﹤0.01% | 3472 |
|
|
2013
Q4 | $3.64M | Sell |
186,612
-62,299
| -25% | -$1.14M | ﹤0.01% | 1955 |
|
|
2013
Q3 | $4.09M | Buy |
248,911
+150,729
| +154% | +$2.42M | 0.01% | 1740 |
|
|
2013
Q2 | $1.47M | Buy |
+98,182
| New | +$1.44M | ﹤0.01% | 2786 |
|
Other funds holding IART
RCMNY
PCMI
VPM
VCM
Citadel Advisors's IART Position: Q1 2026 in Review
Citadel Advisors increased its Integra LifeSciences (IART) stake by 86% in Q1 2026, buying an estimated $2.43M and bringing the position to 476,701 shares worth $4.49M. The position accounts for ﹤0.01% of the portfolio, ranked #4520.
Citadel Advisors first reported a position in IART in Q2 2013 and has held it in 42 quarters since. The position peaked at $22.7M in Q1 2017. 201 funds tracked by Wall St. Rank hold IART as of Q1 2026.
- Citadel Advisors held 476,701 shares of Integra LifeSciences worth $4.49M as of Q1 2026.
- Citadel Advisors bought 220,894 Integra LifeSciences shares in Q1 2026, an estimated $2.43M.
- Integra LifeSciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4520 holding.
- Citadel Advisors first reported a position in Integra LifeSciences in Q2 2013 and has held it in 42 quarters since.
- Citadel Advisors's Integra LifeSciences position peaked at $22.7M in Q1 2017.
- 201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.